Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

Br J Haematol. 2018 Aug;182(3):453-456. doi: 10.1111/bjh.14817. Epub 2017 Jul 24.

Luciano Cascione^{1

2

3}, Andrea Rinaldi¹, Annalisa Chiappella⁴, Ivo Kwee^{1

3

5}, Giovannino Ciccone⁶, Michael Altenbuchinger⁷, Christian Kohler⁷, Umberto Vitolo⁴, Giorgio Inghirami^{8

9

10}, Francesco Bertoni^{1

2}

¹ USI Università della Svizzera Italiana (USI), Institute of Oncology Research (IOR), Bellinzona.
² Oncology Institute of Southern Switzerland, Bellinzona (IOSI).
³ Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
⁴ Ematologia, A.O.U. Citta della Salute e della Scienza di Torino, Turin, Italy.
⁵ Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland.
⁶ Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte (CPO-Piemonte), Turin, Italy.
⁷ Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
⁸ Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
⁹ Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
¹⁰ Department of Pathology, NYU Cancer Center, New York University School of Medicine, New York, NY, USA.

No abstract available

Keywords: Nanostring; diffuse large B cell lymphoma; gene expression; lenalidomide; lymphoma.

Publication types